Li Ming,Li Yong,Huang Zhao,et al.Effect of Serabelisib on human hepatoblastoma HepG2 cells and its mechanisms[J].Journal of Clinical Pediatric Surgery,,19():410-414.[doi:10.3969/j.issn.1671-6353.2020.05.007]
Effect of Serabelisib on human hepatoblastoma HepG2 cells and its mechanisms
- Keywords:
- Liver Neoplasms; PI3K; Serabelisib; HepG2; Cell Proliferation; Apoptosis
- CLC:
- R726;R735.7
- Abstract:
- Objective To explore the inhibitory effect of small molecule inhibitor Serabelisib on the activity of PI3K Akt signaling pathway and its mechanism on the proliferation and apoptosis of human hepatoblastoma cell line.Methods Different concentrations of Serabelisib (0,2,4,8 μmol/L) were employed for treating cells.The inhibition of cellular proliferation was detected by methyl thiazolyl tetrazolium (MTT).The changes of apoptosis were detected by flow cytometry.The cellular activity of PI3K signaling pathway and the cellular expression of apoptosis-related proteins were detected by Western blot.Results A concentration of Serabelisib ≥4 μmol/L had a significant inhibitory effect on cellular proliferation.With a rising concentration of Serabelisib,its inhibitory rate on cellular proliferation gradually increased in a dose/time-dependent manner while cellular apoptotic rate rose significantly in a dose-dependent manner.Western blot indicated that the phosphorylation of Akt,a key kinase in PI3K signaling pathway,decreased and the expression of PARP 89kd fragment spiked in Serabelisib-treated HepG2 cells.Conclusion Serabelisib can inhibit the proliferation and apoptosis by inhibiting PI3K/Akt signal transduction pathway in HepG2 cells.
References:
1 金晟,施诚仁.儿童肝母细胞瘤研究现状[J].临床儿科杂志,2014,32(10):988-992.DOI:10.3969/j.issn.1000-3606.2014.10.31. Jin S,Shi CR.Current research status of pediatric hepatoblastoma[J].Journal of Clinical Pediatrics,2014,32(10):988-992.DOI:10.3969/j.issn.1000-3606.2014.10.31.
2 Lim I,Bondoc AJ,Geller JI,et al.Hepatoblastoma-the evolution of biology,surgery,and transplantation[J].Children (Basel),2018,6(1):E1.DOI:10.3390/children6010001.
3 Trobaugh-Lotrario AD,Katzenstein HM.Chemotherapeutic a-pproaches for newly diagnosed hepatoblastoma:past,present,and future strategies[J].Pediatr Blood Cancer,2012,59(5):809-812.DOI:10.1002/pbc.24219.
4 李勇,肖雅玲,陈朝晖,等.姜黄素对人肝母细胞瘤细胞株HepG2增殖和转移的影响[J].中国普通外科杂志,2014,23(1):117-120.DOI:10.7659/j.issn.1005-6947.2014.01.023. Li Y,Xiao YL,Chen ZH,et al.Effects of Curcumin on proliferation and metastasis of human hepatoblastoma cell line HepG2 in vitro[J].Chin J Gen Surg,2014,23(1):117-120.DOI:10.7659/j.issn.1005-6947.2014.01.023.
5 Marin J,Briz O,Herraez E,et al.Molecular bases of the poor response of liver cancer to chemotherapy[J].Clin Res Hepatol Gastroenterol,2018,42(3):182-192.DOI:10.1016/j.clinre.2017.12.006.
6 Vivanco I,Sawyers CL.The phosphatidylinositol 3-Kinase AKT pathway in human cancer[J].Nat Rev Cancer,2002,2(7):489-501.DOI:10.1038/nrc839.
7 Osaki M,Oshimura M,Ito H.PI3K-Akt pathway:its functions and alterations in human cancer[J].Apoptosis,2004,9(6):667-676.DOI:10.1023/B:APPT.0000045801.15585.dd.
8 Liang J,Slingerland JM.Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression[J].Cell Cycle,2003,2(4):339-345.
9 Janku F,Yap TA,Meric-Bernstam F.Targeting the PI3K pathway in cancer:are we making headway?[J].Nat Rev Clin Oncol,2018,15(5):273-291.DOI:10.1038/nrclinonc.2018.28.
10 Alzahrani AS.PI3K/Akt/mTOR inhibitors in cancer:At the bench and bedside[J].Semin Cancer Biol,2019,59:125-132.DOI:10.1016/j.semcancer.2019.07.009.
11 Arends MJ,Wyllie AH.Apoptosis:mechanisms and roles in pathology[J].Int Rev Exp Pathol,1991,32(32):223-254.DOI:10.1016/b978-0-12-364932-4.50010-1.
12 Rybczynska AA,Boersma HH,de Jong S,et al.Avenues to molecular imaging of dying cells:Focus on cancer[J].Med Res Rev,2018,38(6):1713-1768.DOI:10.1002/med.21495.
13 Ucker DS,Levine JS.Exploitation of apoptotic regulation in cancer[J].Front Immunol,2018,27(9):241.DOI:10.3389/fimmu.2018.00241.
14 Boice A,Bouchier-Hayes L.Targeting apoptotic caspases in cancer[J].Biochim Biophys Acta Mol Cell Res,2020,1867(6):118688.DOI:10.1016/j.bbamcr.2020.118688.
15 Rai N,Sarkar M,Raha S.Piroxicam,a traditional non-steroidal anti-inflammatory drug (NSAID) causes apoptosis by ROS mediated Akt activation[J].Pharmacol Rep,2015,67(6):1215-1223.DOI:10.1016/j.pharep.2015.05.012.
16 Jiang C,Ma S,Hu R,et al.Effect of CXCR4 on apoptosis in osteosarcoma cells via the PI3K/Akt/NF-κβ signaling pathway[J].Cell Physiol Biochem,2018,46(6):2250-2260.DOI:10.1159/000489593.
17 Hartmann W,Küchler J,Koch A,et al.Activation of phosphatidylinositol-3’-kinase/AKT signaling is essential in hepatoblastoma survival[J].Clin Cancer Res,2009,15(14):4538-4545.DOI:10.1158/1078-0432.CCR-08-2878.
18 Xia Z,Zhang N,Ding D.Proliferation and migration of hepatoblastoma cells are mediated by IRS-4 via PI3K/Akt pathways[J].Int J Clin Exp Med,2014,7(10):3763-3769.
19 Juric D,de Bono JS,LoRusso PM,et al.A first-in-human,phase I,dose-escalation study of TAK-117,a selective PI3Kα isoform inhibitor,in patients with advanced solid malignancies[J].Clin Cancer Res,2017,23(17):5015-5023.DOI:10.1158/1078-0432.CCR-16-2888.
20 Patel CG,Rangachari L,Patti M,et al.Characterizing the sources of pharmacokinetic variability for TAK-117 (Serabelisib),an investigational phosphoinositide 3-kinase alpha inhibitor:a clinical biopharmaceutics study to inform development strategy[J].Clin Pharmacol Drug Dev,2019,8(5):637-646.DOI:10.1002/cpdd.613.
Memo
收稿日期:2020-03-18。
基金项目:湖南省卫生健康委课题（编号：C2019021）；湖南省出生缺陷协同防治科技重大专项（编号：2019SK1010）
作者简介:黎明,Email:dawn1212@sina.com